{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:04:27Z","timestamp":1786982667258,"version":"build-2736575974"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s13555-025-01546-4","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T20:12:16Z","timestamp":1759176736000},"page":"3463-3477","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Burden of Alopecia Areata and Management with Baricitinib in the United Arab Emirates: A Narrative Review"],"prefix":"10.1007","volume":"15","author":[{"given":"Hussein Abdel","family":"Dayem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar","family":"Al Hammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Reda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Albreiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Al Naeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Ameen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huda Rajab","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Elrayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gozde","family":"Senay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muna","family":"Al Murrawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"1546_CR1","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s13555-023-00946-8","volume":"13","author":"A Al Hammadi","year":"2023","unstructured":"Al Hammadi A, Parmar NV, Aljefri K, et al. Review on alopecia areata in the Middle East and Africa: landscape and unmet needs. Dermatol Ther. 2023;13:1435\u201364. https:\/\/doi.org\/10.1007\/s13555-023-00946-8.","journal-title":"Dermatol Ther"},{"key":"1546_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18926","author":"A Muntyanu","year":"2023","unstructured":"Muntyanu A, Gabrielli S, Donovan J, et al. The burden of alopecia areata: a scoping review focusing on quality of life, mental health and work productivity. J Eur Acad Dermatol Venereol. 2023. https:\/\/doi.org\/10.1111\/jdv.18926.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1546_CR3","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jaad.2019.08.032","volume":"82","author":"HH Lee","year":"2020","unstructured":"Lee HH, Gwillim E, Patel KR, et al. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis. J Am Acad Dermatol. 2020;82:675\u201382. https:\/\/doi.org\/10.1016\/j.jaad.2019.08.032.","journal-title":"J Am Acad Dermatol"},{"key":"1546_CR4","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/j.1468-3083.2006.01676.x","volume":"20","author":"C Goh","year":"2006","unstructured":"Goh C, Finkel M, Christos PJ, Sinha AA. Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history. J Eur Acad Dermatol Venereol. 2006;20:1055\u201360. https:\/\/doi.org\/10.1111\/j.1468-3083.2006.01676.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1546_CR5","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jaad.2018.01.048","volume":"79","author":"LY Liu","year":"2018","unstructured":"Liu LY, King BA, Craiglow BG. Alopecia areata is associated with impaired health related quality of life: a survey of affected adults and children and their families. J Am Acad Dermatol. 2018;79:556-8.e1. https:\/\/doi.org\/10.1016\/j.jaad.2018.01.048.","journal-title":"J Am Acad Dermatol"},{"key":"1546_CR6","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1007\/s13555-023-00963-7","volume":"13","author":"A Ammoury","year":"2023","unstructured":"Ammoury A, Hegazy R, Al Talhab S, et al. Treatment patterns and unmet needs in the management of alopecia areata: results of a physician\u2019s survey in the Middle East. Dermatol Ther. 2023;13:1801\u201315. https:\/\/doi.org\/10.1007\/s13555-023-00963-7.","journal-title":"Dermatol Ther"},{"key":"1546_CR7","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.jaad.2010.08.032","volume":"65","author":"SY Chu","year":"2011","unstructured":"Chu SY, Chen YJ, Tseng WC, et al. Comorbidity profiles among patients with alopecia areata: the importance of onset age, a nationwide population-based study. J Am Acad Dermatol. 2011;65:949\u201356. https:\/\/doi.org\/10.1016\/j.jaad.2010.08.032.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"1546_CR8","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1111\/1346-8138.16420","volume":"49","author":"JM Jung","year":"2022","unstructured":"Jung JM, Yang HJ, Lee WJ, Won CH, Lee MW, Chang SE. Association between psoriasis and alopecia areata: a systematic review and meta-analysis. J Dermatol. 2022;49(9):912\u20135. https:\/\/doi.org\/10.1111\/1346-8138.16420.","journal-title":"J Dermatol"},{"key":"1546_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19044","author":"W Chen","year":"2023","unstructured":"Chen W, Li S, Cai X, et al. Association between alopecia areata and atopic dermatitis: current evidence. J Eur Acad Dermatol Venereol. 2023. https:\/\/doi.org\/10.1111\/jdv.19044.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1546_CR10","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jaad.2023.10.031","volume":"90","author":"MJ Diaz","year":"2024","unstructured":"Diaz MJ, Jaq Z, Abdi P, Tran JT, Guttman-Yassky E, Ungar B. Association between alopecia areata and atopic dermatitis: a nested case-control study of the All of Us database. J Am Acad Dermatol. 2024;90:607\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2023.10.031.","journal-title":"J Am Acad Dermatol"},{"key":"1546_CR11","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/jdv.19768","volume":"38","author":"L Rudnicka","year":"2024","unstructured":"Rudnicka L, Arenbergerova M, Grimalt R, et al. European expert consensus statement on the systemic treatment of alopecia areata. J Eur Acad Dermatol Venereol. 2024;38:687\u201394. https:\/\/doi.org\/10.1111\/jdv.19768.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1546_CR12","unstructured":"Institute of Dermatology, Thailand. Effectiveness and safety of tofacitinib in patients with extensive and recalcitrant alopecia areata [ClinicalTrials.gov identifier NCT03800979]. US National Institutes of Health, ClinicalTrials.gov. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03800979?term=NCT03800979&draw=2&rank=1. Accessed 2025 Aug 06."},{"key":"1546_CR13","unstructured":"Pfizer. Study to evaluate the efficacy and safety profile of PF-06651600 and PF-06700841 in subjects with alopecia areata [ClinicalTrials.gov identifier NCT02974868]. US National Institutes of Health, ClinicalTrials.gov. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02974868. Accessed 2025 Aug 06."},{"key":"1546_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjidi.2022.100156","volume":"2","author":"B King","year":"2022","unstructured":"King B, Guttman-Yassky E, Peeva E, et al. Safety and efficacy of ritlecitinib and brepocitinib in alopecia areata: results from the crossover open-label extension of the ALLEGRO phase\u00a02a trial. JID Innov. 2022;2:100156. https:\/\/doi.org\/10.1016\/j.sjidi.2022.100156.","journal-title":"JID Innov"},{"key":"1546_CR15","unstructured":"Concert Pharmaceuticals. Study to evaluate the efficacy and safety of CTP-543 in adults with moderate to severe alopecia areata (THRIVE-AA1) (THRIVE-AA1). [ClinicalTrials.gov identifier NCT04518995]. US National Institutes of Health, ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04518995. Accessed 2025 Aug 06."},{"key":"1546_CR16","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.jaad.2024.06.097","volume":"91","author":"B King","year":"2024","unstructured":"King B, Senna MM, Mesinkovska NA, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: results from the phase\u00a03 randomized, controlled trial (THRIVE-AA1). J Am Acad Dermatol. 2024;91:880\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2024.06.097.","journal-title":"J Am Acad Dermatol"},{"key":"1546_CR17","unstructured":"Concert Pharmaceuticals. Study to evaluate the efficacy and safety of CTP-543 in adults with moderate to severe alopecia areata (THRIVE-AA2) (THRIVE-AA2). [ClinicalTrials.gov identifier NCT04797650]. US National Institutes of Health, ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04797650. Accessed 2025 Aug 06."},{"key":"1546_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.955035","volume":"13","author":"M Lensing","year":"2022","unstructured":"Lensing M, Jabbari A. An overview of JAK\/STAT pathways and JAK inhibition in alopecia areata. Front Immunol. 2022;13:955035. https:\/\/doi.org\/10.3389\/fimmu.2022.955035.","journal-title":"Front Immunol"},{"key":"1546_CR19","unstructured":"Eli Lilly and Company. A study of baricitinib (LY3009104) in participants with severe or very severe alopecia areata (BRAVE-AA1) [ClinicalTrials.gov identifier NCT03570749]. US National Institutes of Health, ClinicalTrials.gov. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03570749?term=brave-aa1&draw=2&rank=1. Accessed 2025 Aug 06."},{"key":"1546_CR20","unstructured":"ClinicalTrials.gov. A study of baricitinib (LY3009104) in participants with severe or very severe alopecia areata (BRAVE-AA2) [ClinicalTrials.gov identifier NCT03899259]. US National Institutes of Health, ClinicalTrials.gov. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03899259?term=brave-aa2&draw=2&rank=1. Accessed 2025 Aug 06."},{"key":"1546_CR21","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, Ohyama M, Kwon O, et al. Two phase\u00a03 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386:1687\u201399. https:\/\/doi.org\/10.1056\/NEJMoa2110343.","journal-title":"N Engl J Med"},{"key":"1546_CR22","unstructured":"Pfizer. Long-term PF-06651600 for the treatment of alopecia areata (ALLEGRO-LT) [ClinicalTrials.gov identifier NCT04006457]. US National Institutes of Health, ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04006457. Accessed 2025 Aug 06."},{"key":"1546_CR23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/bjd\/ljae365","volume":"192","author":"M Piliang","year":"2025","unstructured":"Piliang M, Soung J, King B, et al. Efficacy and safety of the oral Janus kinase 3\/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24\u2005months: integrated analysis of the ALLEGRO phase\u00a0IIb\/III and long-term phase\u00a0III clinical studies in alopecia areata. Br J Dermatol. 2025;192:215\u201327. https:\/\/doi.org\/10.1093\/bjd\/ljae365.","journal-title":"Br J Dermatol"},{"key":"1546_CR24","unstructured":"National Institute of Allergy and Infectious Diseases (NIAID). Evaluate the efficacy and safety of ruxolitinib on hair regrowth in patients with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED)-associated alopecia areata [ClinicalTrials.gov identifier NCT05398809]. US National Institutes of Health, ClinicalTrials.gov. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05398809. Accessed 2025 Aug 06."},{"key":"1546_CR25","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s40265-023-01873-w","volume":"83","author":"E Freitas","year":"2023","unstructured":"Freitas E, Guttman-Yassky E, Torres T. Baricitinib for the treatment of alopecia areata. Drugs. 2023;83:761\u201370. https:\/\/doi.org\/10.1007\/s40265-023-01873-w.","journal-title":"Drugs"},{"key":"1546_CR26","doi-asserted-by":"publisher","unstructured":"Blair HA. Ritlecitinib: first approval [published erratum appears in Drugs. 2023; 83:1457]. Drugs. 2023; 83:1315\u201321. https:\/\/doi.org\/10.1007\/s40265-023-01928-y","DOI":"10.1007\/s40265-023-01928-y"},{"key":"1546_CR27","unstructured":"GOV.UK. MHRA authorises Litfulo as a treatment for severe alopecia areata in adults and adolescents 12\u00a0years and older [press release]. 2023 Nov 01. https:\/\/www.gov.uk\/government\/news\/mhra-authorises-litfulo-as-a-treatment-for-severe-alopecia-areata-in-adults-and-adolescents-12-years-and-older. Accessed 2025 Aug 06."},{"key":"1546_CR28","unstructured":"European Medicines Agency. Olumiant: summary of product characteristics. Updated 12 November 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/olumiant-epar-product-information_en.pdf. Accessed 2025 Aug 06."},{"key":"1546_CR29","unstructured":"Pfizer Japan Inc. [Oral JAK3\/TEC family kinase inhibitor \"Litfulo\u00ae capsules 50mg (generic name: ritlecitinib tosylate)\" obtained manufacturing and marketing approval to meet the unmet needs of patients with alopecia areata] [media release]. https:\/\/www.pfizer.co.jp\/pfizer\/company\/press\/2023\/2023-06-26. Last update Jun 26, 2023. Accessed July 15, 2025."},{"key":"1546_CR30","unstructured":"United Arab Emirates Ministry of Health and Prevention. Registered Medical Product Directory. Litfulo\u00ae 50mg. Updated April 9, 2024. https:\/\/mohap.gov.ae\/en\/registered-medical-product-directory?keyword=litfulo. Accessed 2025 Aug 06."},{"key":"1546_CR31","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jaad.2020.06.047","volume":"85","author":"A Toussi","year":"2021","unstructured":"Toussi A, Barton VR, Le ST, Agbai ON, Kiuru M. Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: a systematic review. J Am Acad Dermatol. 2021;85:162\u201375. https:\/\/doi.org\/10.1016\/j.jaad.2020.06.047.","journal-title":"J Am Acad Dermatol"},{"key":"1546_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.874677","volume":"13","author":"H Wang","year":"2022","unstructured":"Wang H, Pan L, Wu Y. Epidemiological trends in alopecia areata at the global, regional, and national levels. Front Immunol. 2022;13:874677. https:\/\/doi.org\/10.3389\/fimmu.2022.874677.","journal-title":"Front Immunol"},{"key":"1546_CR33","doi-asserted-by":"publisher","first-page":"125","DOI":"10.4103\/0972-6748.181724","volume":"24","author":"SB Karia","year":"2015","unstructured":"Karia SB, De Sousa A, Shah N, Sonavane S, Bharati A. Psychiatric morbidity and quality of life in skin diseases: a comparison of alopecia areata and psoriasis. Indian J Psychiatry. 2015;24:125\u20138. https:\/\/doi.org\/10.4103\/0972-6748.181724.","journal-title":"Indian J Psychiatry"},{"key":"1546_CR34","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1007\/s13555-023-01057-0","volume":"13","author":"S Va\u00f1\u00f3-Galv\u00e1n","year":"2023","unstructured":"Va\u00f1\u00f3-Galv\u00e1n S, Blume-Peytavi U, Farrant P, et al. Physician- and patient-reported severity and quality of life impact of alopecia areata: results from a real-world survey in five European countries. Dermatol Ther (Heidelb). 2023;13:3121\u201335. https:\/\/doi.org\/10.1007\/s13555-023-01057-0.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1546_CR35","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1111\/1346-8138.16839","volume":"50","author":"P George","year":"2023","unstructured":"George P, Jagun O, Liu Q, et al. Prevalence of autoimmune and inflammatory diseases and mental health conditions among an alopecia areata cohort from a US administrative claims database. J Dermatol. 2023;50:1121\u20138. https:\/\/doi.org\/10.1111\/1346-8138.16839.","journal-title":"J Dermatol"},{"key":"1546_CR36","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s13555-024-01133-z","volume":"14","author":"S Va\u00f1\u00f3-Galv\u00e1n","year":"2024","unstructured":"Va\u00f1\u00f3-Galv\u00e1n S, Egeberg A, Piraccini BM, et al. Characteristics and management of patients with alopecia areata and selected comorbid conditions: results from a survey in five European countries. Dermatol Ther (Heidelb). 2024;14:1027\u201337. https:\/\/doi.org\/10.1007\/s13555-024-01133-z.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1546_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.11","volume":"3","author":"C Pratt","year":"2017","unstructured":"Pratt C, King LE, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers. 2017;3:17011. https:\/\/doi.org\/10.1038\/nrdp.2017.11.","journal-title":"Nat Rev Dis Primers"},{"key":"1546_CR38","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s40257-017-0297-6","volume":"18","author":"J Cervantes","year":"2017","unstructured":"Cervantes J, Fertig RM, Maddy A, Tosti A. Alopecia areata of the beard: a review of the literature. Am J Clin Dermatol. 2017;18:789\u201396. https:\/\/doi.org\/10.1007\/s40257-017-0297-6.","journal-title":"Am J Clin Dermatol"},{"key":"1546_CR39","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.jaad.2019.10.058","volume":"82","author":"KLS Kerkemeyer","year":"2020","unstructured":"Kerkemeyer KLS, John JM, Sinclair R, Bhoyrul B. Response of alopecia areata of the beard to oral tofacitinib. J Am Acad Dermatol. 2020;82:1228\u201330. https:\/\/doi.org\/10.1016\/j.jaad.2019.10.058.","journal-title":"J Am Acad Dermatol"},{"key":"1546_CR40","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.jaad.2022.11.028","volume":"88","author":"A Moussa","year":"2023","unstructured":"Moussa A, Eisman S, Sinclair RD, Bhoyrul B. Treatment of alopecia areata of the beard with baricitinib. J Am Acad Dermatol. 2023;88:948\u201350. https:\/\/doi.org\/10.1016\/j.jaad.2022.11.028.","journal-title":"J Am Acad Dermatol"},{"key":"1546_CR41","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/bjd.21055","volume":"187","author":"AE Macbeth","year":"2022","unstructured":"Macbeth AE, Holmes S, Harries M, et al. The associated burden of mental health conditions in alopecia areata: a population-based study in UK primary care. Br J Dermatol. 2022;187:73\u201381. https:\/\/doi.org\/10.1111\/bjd.21055.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1546_CR42","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/1346-8138.16888","volume":"50","author":"M Ohyama","year":"2023","unstructured":"Ohyama M, Kamei K, Yuasa A, Anderson P, Milligan G, Sakaki-Yumoto M. Economic burden of alopecia areata: a study of direct and indirect cost in Japan using real-world data. J Dermatol. 2023;50(10):1246\u201354. https:\/\/doi.org\/10.1111\/1346-8138.16888.","journal-title":"J Dermatol"},{"key":"1546_CR43","doi-asserted-by":"publisher","first-page":"S546","DOI":"10.1016\/j.jval.2023.09.2937","volume":"26","author":"A Al Hammadi","year":"2023","unstructured":"Al Hammadi A, Farghaly M, Al Dallal S, et al. SA28 Evaluation of disease epidemiology, comorbidities, treatment patterns, and healthcare resource utilization of alopecia areata in United Arab Emirates: a retrospective claims database study. Value Health. 2023;26:S546.","journal-title":"Value Health"},{"key":"1546_CR44","doi-asserted-by":"crossref","unstructured":"Al Hammadi A, Farghaly M, Al Dallal S, et al. SA28 Evaluation of disease epidemiology, comorbidities, treatment patterns, and healthcare resource utilization of alopecia areata in United Arab Emirates: a retrospective claims database study. SA28 [poster]. ISPOR Europe; 2023 Nov 12\u201315; Copenhagen.","DOI":"10.1016\/j.jval.2023.09.2937"},{"issue":"6","key":"1546_CR45","doi-asserted-by":"publisher","first-page":"725","DOI":"10.4103\/idoj.idoj_176_22","volume":"13","author":"R Dhurat","year":"2022","unstructured":"Dhurat R, Sharma R. A practical approach to the treatment of alopecia areata. Indian Dermatol Online J. 2022;13(6):725\u20138. https:\/\/doi.org\/10.4103\/idoj.idoj_176_22.","journal-title":"Indian Dermatol Online J"},{"key":"1546_CR46","doi-asserted-by":"publisher","first-page":"20","DOI":"10.4103\/0974-7753.82123","volume":"3","author":"C Kuldeep","year":"2011","unstructured":"Kuldeep C, Singhal H, Khare AK, Mittal A, Gupta LK, Garg A. Randomized comparison of topical betamethasone valerate foam, intralesional triamcinolone acetonide and tacrolimus ointment in management of localized alopecia areata. Int J Trichology. 2011;3:20\u20134. https:\/\/doi.org\/10.4103\/0974-7753.82123.","journal-title":"Int J Trichology"},{"key":"1546_CR47","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.3390\/biom10071002","volume":"10","author":"J Angelini","year":"2020","unstructured":"Angelini J, Talotta R, Roncato R, et al. JAK-inhibitors for the treatment of rheumatoid arthritis: a focus on the present and an outlook on the future. Biomolecules. 2020;10:1002. https:\/\/doi.org\/10.3390\/biom10071002.","journal-title":"Biomolecules"},{"key":"1546_CR48","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","volume":"20","author":"L Xing","year":"2014","unstructured":"Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20:1043\u20139. https:\/\/doi.org\/10.1038\/nm.3645.","journal-title":"Nat Med"},{"key":"1546_CR49","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jaad.2020.04.138","volume":"84","author":"JW Glickman","year":"2021","unstructured":"Glickman JW, Dubin C, Renert-Yuval Y, et al. Cross-sectional study of blood biomarkers of patients with moderate to severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation. J Am Acad Dermatol. 2021;84:370\u201380. https:\/\/doi.org\/10.1016\/j.jaad.2020.04.138.","journal-title":"J Am Acad Dermatol"},{"key":"1546_CR50","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/bjd\/ljad253","volume":"189","author":"B King","year":"2023","unstructured":"King B, Shapiro J, Ohyama M, et al. When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase\u00a0III trials. Br J Dermatol. 2023;189:666\u201373. https:\/\/doi.org\/10.1093\/bjd\/ljad253.","journal-title":"Br J Dermatol"},{"key":"1546_CR51","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40257-023-00764-w","volume":"24","author":"O Kwon","year":"2023","unstructured":"Kwon O, Senna MM, Sinclair R, et al. Efficacy and safety of baricitinib in patients with severe alopecia areata over 52\u00a0weeks of continuous therapy in two phase\u00a0III trials (BRAVE AA1 and BRAVE-AA2). Am J Clin Dermatol. 2023;24:443\u201351. https:\/\/doi.org\/10.1007\/s40257-023-00764-w.","journal-title":"Am J Clin Dermatol"},{"key":"1546_CR52","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/jdv.19665","volume":"38","author":"M Senna","year":"2024","unstructured":"Senna M, Mostaghimi A, Ohyama M, et al. Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2. J Eur Acad Dermatol Venereol. 2024;38:583\u201393. https:\/\/doi.org\/10.1111\/jdv.19665.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1546_CR53","doi-asserted-by":"crossref","unstructured":"Senna M, Mostaghimi A, Ohyama M, et al. Long-term efficacy of baricitinib in alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2 [poster]. American Academy of Dermatology; 2024; San Diego.","DOI":"10.1016\/j.jaad.2024.07.996"},{"key":"1546_CR54","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2268764","volume":"34","author":"L Gargiulo","year":"2023","unstructured":"Gargiulo L, Ibba L, Vignoli CA, et al. Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience. J Dermatolog Treat. 2023;34:2268764. https:\/\/doi.org\/10.1080\/09546634.2023.2268764.","journal-title":"J Dermatolog Treat"},{"key":"1546_CR55","doi-asserted-by":"publisher","first-page":"4910","DOI":"10.1007\/s12325-022-02281-4","volume":"39","author":"T Bieber","year":"2022","unstructured":"Bieber T, Feist E, Irvine AD, et al. A review of safety outcomes from clinical trials of aricitinib in rheumatology, dermatology and COVID-19. Adv Ther. 2022;39:4910\u201360. https:\/\/doi.org\/10.1007\/s12325-022-02281-4.","journal-title":"Adv Ther"},{"key":"1546_CR56","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/bjd\/ljac059","volume":"188","author":"B King","year":"2023","unstructured":"King B, Mostaghimi A, Shimomura Y, et al. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. Br J Dermatol. 2023;188:218\u201327. https:\/\/doi.org\/10.1093\/bjd\/ljac059.","journal-title":"Br J Dermatol"},{"key":"1546_CR57","unstructured":"European Medicines Agency. Olumiant: procedural steps taken and scientific information after the authorisation. Amsterdam: EMA; 2024. https:\/\/www.ema.europa.eu\/en\/documents\/procedural-steps-after\/olumiant-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf. Accessed 2025 Aug 2025."},{"key":"1546_CR58","doi-asserted-by":"publisher","unstructured":"Ameen A, Dhaheri AA, Reda AM, et al. Consensus recommendations for the management of atopic dermatitis in the United Arab Emirates [published erratum appears in Dermatol Ther (Heidelb). 2024;14:2927\u201328]. Dermatol Ther (Heidelb). 2024;14:2299\u2013330. https:\/\/doi.org\/10.1007\/s13555-024-01247-4.","DOI":"10.1007\/s13555-024-01247-4"},{"key":"1546_CR59","unstructured":"Eli Lilly and Company. A study of baricitinib (LY3009104) in children from 6\u00a0years to less than 18\u00a0years of age with alopecia areata (BRAVE-AA-PEDS) [ClinicalTrials.gov identifier NCT05723198]. US National Institutes of Health, ClinicalTrials.gov. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05723198. Accessed 2025 Aug 06."},{"key":"1546_CR60","unstructured":"Passeron T, Soung J, Kwon O, et al. Baricitinib provides significant hair regrowth in adolescents with severe alopecia areata: 36-week efficacy and safety results from a Phase\u00a03 randomized, controlled trial. American Academy of Dermatology Annual Meeting. 2025 Mar 7\u201311; Orlando."},{"issue":"1","key":"1546_CR61","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/bjd\/ljad096","volume":"189","author":"A Torrelo","year":"2023","unstructured":"Torrelo A, Rewerska B, Galimberti M, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase\u00a0III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). Br J Dermatol. 2023;189(1):23\u201332. https:\/\/doi.org\/10.1093\/bjd\/ljad096.","journal-title":"Br J Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01546-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01546-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01546-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T09:22:15Z","timestamp":1763198535000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01546-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":61,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1546"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01546-4","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hussein Abdel Dayem has received honoraria from AbbVie, Eli Lilly and Company, Johnson & Johnson, Leo, Novartis, and Pfizer. Ayman Al Naeem is a board member at Emirates Dermatology Society. Ahmed Ameen has received payment or honoraria for lectures, presentations, speakers bureaus, abstract (and subsequent poster) writing, or educational events from AbbVie, Eli Lilly and Company, Janssen, Leo, Pfizer, and Sanofi. Mohamed Elrayes and Gozde Senay are employees of and minor stakeholders in Eli Lilly and Company. Anwar Al Hammadi, Ashraf Reda, Fatima Albreiki, Huda Rajab Ali, Mohamed Ahmed and Muna Al Murrawi have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}